Risk of lymphoproliferative disorders after bone marrow transplantation : A multi-institutional study

• Published in: Blood 1999-10, Vol.94 (7), p.2208-2216
• Main Authors: CURTIS, R. E, TRAVIS, L. B, SHRINER, D. A, WEISDORF, D. J, KOLB, H.-J, SULLIVAN, K. M, SOBOCINSKI, K. A, GALE, R. P, HOOVER, R. N, FRAUMENI, J. F, DEEG, H. J, ROWLINGS, P. A, SOCIE, G, KINGMA, D. W, BANKS, P. M, JAFFE, E. S, SALE, G. E, HOROWITZ, M. M, WITHERSPOON, R. P
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Anemia, Aplastic - therapy; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Biological and medical sciences; Bone Marrow Transplantation - adverse effects; Bone Marrow Transplantation - immunology; Bone marrow, stem cells transplantation. Graft versus host reaction; Child; Cohort Studies; Female; Graft vs Host Disease - prevention & control; Histocompatibility Testing; Humans; Immunosuppression - methods; Immunosuppressive Agents - therapeutic use; Leukemia - therapy; Lymphocyte Depletion; Lymphoproliferative Disorders - epidemiology; Male; Medical sciences; Postoperative Complications - epidemiology; Risk Factors; T-Lymphocytes - immunology; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Transplantation, Homologous; United States - epidemiology
• ISSN: 0006-4971; 1528-0020

We evaluated 18,014 patients who underwent allogeneic bone marrow transplantation (BMT) at 235 centers worldwide to examine the incidence of and risk factors for posttransplant lymphoproliferative disorders (PTLD). PTLD developed in 78 recipients, with 64 cases occurring less than 1 year after transplantation. The cumulative incidence of PTLD was 1.0% +/- 0.3% at 10 years. Incidence was highest 1 to 5 months posttransplant (120 cases/10,000 patients/yr) followed by a steep decline to less than 5/10,000/yr among >/=1-year survivors. In multivariate analyses, risk of early-onset PTLD (